GREY:IMVIF - Post by User
Comment by
Biotech010on Apr 07, 2021 2:26pm
312 Views
Post# 32950597
RE:RE:RE:RE:Hmm. So, collaboration continues?
RE:RE:RE:RE:Hmm. So, collaboration continues? the trial is designed to get the accelarated approval. They need to repeat in a larger number of patients the data that they had in the PDL-1 positive patient population.
That is want they wanted to hear fromt the FDA and that's what they got. So if in Q1 2022 the interim results point to the same results.... jackpot.
For now, it's a waiting game. I expect Fred and his team to prep up investors confidence with some stunning COVID results / launch of phase 1/2 soon.